Polymorphic forms of naltrexone
US-9221830-B2 · Dec 29, 2015 · US
Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US9102680B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9102680-B2 |
| Application number | US-201213682878-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2012 |
| Priority date | Mar 29, 2007 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a new forms of (R)—N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
First claim
Opening claim text (preview).
We claim: 1. Form D of Compound 1: where the compound is in the (R) configuration with respect to the nitrogen, and wherein the compound has an X-ray powder diffraction pattern comprising all of the peaks at about 7.66, 8.42, 14.79, and 21.06 degrees 2-theta. 2. Form D of Compound 1 according to claim 1 , wherein the X-ray powder diffraction pattern…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9102680B2 cover?
- The present invention provides a new forms of (R)—N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
- Who is the assignee on this patent?
- Progenics Pharm Inc, Wyeth Llc, Wyeth Llc, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07D489/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).